1Rich S, Koufmann E, Levy PS, et al. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med, 1992;327(2) :76～81 被引量：1
2Houde C, Bohn DJ, Freedom RM, et al. Prifile of paediatric patients with pulmonary hypertention judged by responsiveness to vasdilators. J Br Heart, 1993; 70 (5): 461 ～ 468 被引量：1
3Shapiro SM,Oudiz R J, Cao T, et al. Primary pulmonary hypertension. improved long- term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardoil, 1997;30(2) :343～349 被引量：1
4Eronen M, Pohjavuori M,Andersson S, et al. Prostaoyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardol, 1997; 18(1): 3～ 7 被引量：1
5Archer S L, Mike D, Crow J,et al. A Placebo- controlled trial of prostacyclin in acute respiratory failure in COPD. Chest,1996; 109(3) :750～755 被引量：1
6Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long -term infusion of prostacyclin( epoprostenol)on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Circulation, 1997;95(6): 1479～1486 被引量：1
7Escudero J,Navarro J,Padua A,et al. Hemodynamic changes with enalapril in pulmonary aterial hypertension secondary to congenital heart disease. Chest, 1987; 91 (3): 351 ～ 355 被引量：1
8Linz W, Wiemer G, Gohlke P, et al. Contribution of kinins to the cardiovascular actions of angiotensin - converting enzyme inhibitors. Pharmcol Rev, 1995; 47 (1): 25～ 49 被引量：1
9Turanlahti MI, Laitinen PO, Sarna SJ, et al. Nitric oxide, oxygen and prostacyclin in children with pulmonary disease.Heart, 1998;79(2): 169～ 174 被引量：1
10Lunn RJ. Inhaled NO therapy. Mayo Clin Proc, 1995;70(3):247- 255 被引量：1
